# Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge

> **NCT03416036** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 64 (actual)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** TetraVax-DV-TV003 (TV003)
- **BIOLOGICAL:** rDEN2Δ30-7169 (DENV-2)
- **BIOLOGICAL:** rDEN3Δ30 (DENV-3)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03416036
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2019-01-17
- **Final completion:** 2019-06-04
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03416036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03416036, "Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03416036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*